BioXcel Therapeutics (BTAI) Stock Price, News & Analysis

Company Overview

BioXcel Therapeutics, Inc., a commercial-stage biopharmaceutical company, engages in utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology. The company's drug re-innovation approach leverages existing approved drugs and/or clinically validated product candidates together with big data and proprietary machine learning algorithms to identify new therapeutic indices. Its commercial product, IGALMI, a sublingual film formulation of dexmedetomidine for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults. The company also continues to conduct clinical trials evaluating BXCL501 for the acute treatment of agitation in Alzheimer's disease patients, and for adjunctive treatment of patients with major depressive disorder, as well as in the community for agitation associated with bipolar disorders and schizophrenia. In addition, it is developing BXCL502 as a potential therapy for chronic agitation in dementia; and BXCL701, an investigational, orally innate immunity activator for the treatment of aggressive forms of prostate cancer, pancreatic cancer, and other solid and liquid tumors; BXCL503, a drug candidate to target apathy in dementia; and BXCL504, a drug candidate to target aggression in dementia. BioXcel Therapeutics, Inc. was incorporated in 2017 and is headquartered in New Haven, Connecticut.

Key Stats

• Today's Range: $2.25 to $2.47
• 50-Day Range: $2.27 to $9.17
• 52-Week Range: $2.16 to $56.00
• Volume: 85,199 shs
• Average Volume: 207,890 shs
• Market Capitalization: $7.19 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $37.00
• Consensus Rating: Hold

BioXcel Therapeutics Stock Analysis - MarketRank™

BioXcel Therapeutics scored higher than 83% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.1 / 5
• Analyst Rating: Hold

Consensus Rating

BioXcel Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.25, and is based on 2 buy ratings, 1 hold rating, and 1 sell rating.

Amount of Analyst Coverage

BioXcel Therapeutics has only been the subject of 3 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for BioXcel Therapeutics are expected to grow in the coming year, from ($24.39) to ($16.32) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of BioXcel Therapeutics is -0.07, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of BioXcel Therapeutics is -0.07, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Short Interest

• Score: 4.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

9.72% of the float of BioXcel Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

BioXcel Therapeutics has a short interest ratio ("days to cover") of 2.1, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in BioXcel Therapeutics has recently decreased by 84.33%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

BioXcel Therapeutics does not currently pay a dividend.

Dividend Growth

BioXcel Therapeutics does not have a long track record of dividend growth.

Sustainability and ESG

• Score: 4.5 / 5
• Environmental Score: -1.13

Percentage of Shares Shorted

9.72% of the float of BioXcel Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

BioXcel Therapeutics has a short interest ratio ("days to cover") of 2.1, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in BioXcel Therapeutics has recently decreased by 84.33%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 0.6 / 5
• News Sentiment: N/A

Search Interest

14 people have searched for BTAI on MarketBeat in the last 30 days. This is an increase of 250% compared to the previous 30 days.

MarketBeat Follows

Only 3 people have added BioXcel Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days.

Company Ownership

• Score: 2.5 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, BioXcel Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $1,381.00 in company stock.

Percentage Held by Insiders

21.20% of the stock of BioXcel Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

Only 30.68% of the stock of BioXcel Therapeutics is held by institutions.

BTAI Stock Analysis - Frequently Asked Questions

How have BTAI shares performed this year?

BioXcel Therapeutics' stock was trading at $5.9824 on January 1st, 2025. Since then, BTAI shares have decreased by 60.6% and is now trading at $2.3550.
View the best growth stocks for 2025 here.

How were BioXcel Therapeutics' earnings last quarter?

BioXcel Therapeutics, Inc. (NASDAQ:BTAI) issued its earnings results on Tuesday, August, 6th. The company reported ($3.36) earnings per share for the quarter, beating analysts' consensus estimates of ($12.16) by $8.80. The business earned $1.10 million during the quarter, compared to the consensus estimate of $0.80 million.

When did BioXcel Therapeutics' stock split?

BioXcel Therapeutics's stock reverse split before market open on Monday, February 10th 2025. The 1-16 reverse split was announced on Thursday, February 6th 2025. The number of shares owned by shareholders was adjusted after the closing bell on Friday, February 7th 2025. An investor that had 100 shares of stock prior to the reverse split would have 6 shares after the split.

When did BioXcel Therapeutics IPO?

BioXcel Therapeutics (BTAI) raised $60 million in an initial public offering on Thursday, March 8th 2018. The company issued 5,000,000 shares at a price of $11.00-$13.00 per share. Barclays, UBS Investment Bank and BMO Capital Markets served as the underwriters for the IPO and Canaccord Genuity was co-manager.

Who are BioXcel Therapeutics' major shareholders?

Top institutional shareholders of BioXcel Therapeutics include Geode Capital Management LLC (0.63%), Wells Fargo & Company MN (0.40%), Millennium Management LLC (0.21%) and Renaissance Technologies LLC (0.16%). Insiders that own company stock include Vimal Mehta, Richard I Steinhart, Vincent O'neill, Matthew T Wiley, Frank Yocca and Krishnan Nandabalan.
View institutional ownership trends.

How do I buy shares of BioXcel Therapeutics?

Shares of BTAI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of BioXcel Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that BioXcel Therapeutics investors own include NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Broadcom (AVGO), CrowdStrike (CRWD), Adobe (ADBE) and Saia (SAIA).

Company Calendar

• Last Earnings: 8/06/2024
• Today: 2/20/2025
• Next Earnings (Estimated): 5/07/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:BTAI
• CUSIP: N/A
• CIK: 1720893
• Web: www.bioxceltherapeutics.com
• Phone: (475) 238-6837
• Fax: N/A
• Employees: 90
• Year Founded: 2017

Price Target and Rating

• Average Stock Price Target: $37.00
• High Stock Price Target: $80.00
• Low Stock Price Target: $4.00
• Potential Upside/Downside: +1,451.4%
• Consensus Rating: Hold
• Rating Score (0-4): 2.25
• Research Coverage: 4 Analysts

Profitability

• EPS (Most Recent Fiscal Year): ($34.56)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-179,050,000.00
• Net Margins: -3,119.33%
• Pretax Margin: -3,119.33%
• Return on Equity: N/A
• Return on Assets: -105.04%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 1.87
• Quick Ratio: 1.81

Sales & Book Value

• Annual Sales: $1.38 million
• Price / Sales: 5.36
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($30.21) per share
• Price / Book: -0.08

Miscellaneous

• Outstanding Shares: 3,100,000
• Free Float: 2,444,000
• Market Cap: $7.39 million
• Optionable: Optionable
• Beta: -0.01